Silver Book Fact

After one year, 73 percent of non-small-cell lung cancer patients with the EGFR genetic mutation who were treated with a tyrosine kinase inhibitor had survived, compared to 15 percent who received traditional chemotherapy.

Aspinall, M and R Hamermesh. Realizing the Promise of Personalized Medicine. Harvard Bus Rev. 2007; 85(10): 108-17. https://hbr.org/2007/10/realizing-the-promise-of-personalized-medicine

Reference

Title
Realizing the Promise of Personalized Medicine
Publication
Harvard Bus Rev
Publication Date
2007
Authors
Aspinall, M and R Hamermesh
Volume & Issue
Volume 85, Issue 10
Pages
108-17
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • According to the Pharmaceutical Research and Manufacturers of America, a cancer medicine in development is designed to induce a powerful immune response to melanoma.  
  • Between August 2004 and July 2014, the FDA approved: Six new anticancer therapeutics Five new uses for previously approved anticancer therapeutics Two new uses for imaging agents One new use for a screening test  
  • Cancer Survival Rate Increasing  
  • Medicines Prevent Cancer Recurrence: New breast cancer drug greatly reduces recurrence and death (5 to 10 years after diagnosis in postmenopausal women)  
  • Since 1980, 83 percent of gains in life expectancy for cancer patients have been attributable to new treatments.